New drug research and development in China is rapidly rising. Since 2016, domestic pharmaceutical enterprises have been accelerating with the help of capital. China's pharmaceutical industry is gradually transforming from traditional generic drug production to innovative drugs with high added value. Under this background, since DIA China's first drug research and innovation conference, DIA China's second drug research and innovation conference was solemnly held in BioBAY, Suzhou, which is the " silicon valley" of China's innovative drug research and development from October 24 to 26 this year. The purpose of the meeting is to provide a learning and sharing platform for domestic innovative drug research professionals and to gain an all-round understanding of the professional knowledge of the early stages of new drug research and development. The meeting attracted more than 500 domestic innovative drug research and development professionals and the media to attend.

The chairman of the meeting, Dr. Lu Xianping who is the president and chief scientific officer of CHIPSCREEN BIOSCIENCES, delivered a speech at the meeting and described the industry innovation for the guests. He pointed out that today's Chinese pharmaceutical industry has undergone a very significant turning point. In the past ten years, successful cases of original new drug research and development by local enterprises have begun to emerge. The financing environment for innovative enterprises has greatly improved. The major national special support has further boosted the great changes in the pharmaceutical industry. Pharmaceutical administration has taken great and firm steps in supporting innovation and science. China's new drug research and development has rapidly risen. In the future, with the promotion of the 2030 goal of healthy China and the rapid progress of global biomedicine, how to turn the latest innovative scientific research results into sharp tools for curing diseases and saving lives and make the innovative research results serve the world is the development road of Chinese medicine industry!

The conference has 6 major topics and 12 sub-conferences covering the knowledge system of early drug research. During the conference, experts at home and abroad share their own experiences so that participants can enjoy a knowledge feast of drug innovation on the platform of DIA's authority, neutrality and internationalization.